Lyell Immunopharma annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Debt-to-Assets Ratio Growth & History (LYEL)
Lyell Immunopharma's debt-to-assets ratio was 0.15 for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.15 | 0.03 | +24.83% |
| 2024 | 2024-12-31 | 0.12 | 0.04 | +42.64% |
| 2023 | 2023-12-31 | 0.08 | 0.01 | +16.63% |
| 2022 | 2022-12-31 | 0.07 | 0.01 | +20.04% |
| 2021 | 2021-12-31 | 0.06 | 0.00 | +0.12% |
| 2020 | 2020-12-31 | 0.06 | — | — |
Lyell Immunopharma quarterly debt-to-assets ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.15 | 0.01 | +4.75% |
| Q1 2026 | 2026-03-31 | 0.14 | 0.01 | +4.89% |
| Q4 2025 | 2025-12-31 | 0.15 | 0.03 | +24.83% |
| Q3 2025 | 2025-09-30 | 0.13 | 0.04 | +37.52% |
| Q2 2025 | 2025-06-30 | 0.14 | 0.05 | +55.30% |
| Q1 2025 | 2025-03-31 | 0.13 | 0.04 | +49.15% |
| Q4 2024 | 2024-12-31 | 0.12 | 0.04 | +42.64% |
| Q3 2024 | 2024-09-30 | 0.09 | 0.01 | +16.35% |
| Q2 2024 | 2024-06-30 | 0.09 | 0.01 | +16.39% |
| Q1 2024 | 2024-03-31 | 0.09 | 0.01 | +17.67% |
| Q4 2023 | 2023-12-31 | 0.08 | 0.01 | +16.63% |
| Q3 2023 | 2023-09-30 | 0.08 | 0.01 | +17.76% |
| Q2 2023 | 2023-06-30 | 0.08 | 0.01 | +19.63% |
| Q1 2023 | 2023-03-31 | 0.08 | 0.01 | +17.91% |
| Q4 2022 | 2022-12-31 | 0.07 | 0.01 | +20.04% |
| Q3 2022 | 2022-09-30 | 0.07 | 0.01 | +23.07% |
| Q2 2022 | 2022-06-30 | 0.07 | 0.01 | +28.15% |
| Q1 2022 | 2022-03-31 | 0.06 | — | — |
| Q4 2021 | 2021-12-31 | 0.06 | 0.00 | +0.12% |
| Q3 2021 | 2021-09-30 | 0.06 | — | — |
| Q2 2021 | 2021-06-30 | 0.05 | — | — |
| Q4 2020 | 2020-12-31 | 0.06 | — | — |
Lyell Immunopharma debt-to-assets ratio trends
Over the last five fiscal years, Lyell Immunopharma's debt-to-assets ratio increased from 0.06 to 0.15, a change of 0.09. The latest reported quarter, Q2 2026, shows 0.15.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗